• Akari Therapeutics completed a consolidated closing of its private placement on June 26, issuing 980,395 unregistered ADSs or prefunded warrants.
• The sale completed the remaining ADS issuance under a May 22 securities purchase agreement that covered 1,470,588 ADSs in total.
• The company combined the previously planned second and third tranches into the June 26 closing, with no other changes to the agreement.
• Delivery of Series H, Series I, and Series J warrants remains contingent on shareholder approval at the June 30 annual meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-030341), on June 26, 2026, and is solely responsible for the information contained therein.